艾司西酞普兰用于妊娠期抑郁的安全性研究探讨

doi:10.12092/j.issn.1009-2501.2019.09.017

中国临床药理学与治疗学 ›› 2019, Vol. 24 ›› Issue (9): 1070-1074.doi: 10.12092/j.issn.1009-2501.2019.09.017

艾司西酞普兰用于妊娠期抑郁的安全性研究探讨

王思捷，张峻，李骞，黄桦，王晶晶，周琼，姚勤

昆明医科大学第一附属医院临床药学科，昆明 650032，云南

收稿日期:2019-04-15 修回日期:2019-06-27 出版日期:2019-09-26 发布日期:2019-09-26
通讯作者: 姚勤，女，副主任药师，硕士，研究方向：体内药物分析。 Tel：0871-65324888-2550 E-mail：2335799@qq.com
作者简介:王思捷，女，硕士研究生，研究方向：临床药理学。 Tel：0871-65324888-2550 E-mail：691485171@qq.com
基金资助:
云南省教育厅科学研究基金项目（2017zDX166）；云南省卫生科技计划项目（2017NS069、2017NS070）；云南省高层次卫生计生技术人才培养专项经费资助（L-201614、H-2017050、H-2017051、H-2017053）；云南省科技厅-昆明医科大学应用基础研究联合专项重点项目（2018FE001（-167））

Research progress on the safety and effectiveness of escitalopram in the treatment of pregnant women with depression

WANG Sijie，ZHANG Jun，LI Qian，HUANG Hua，WANG Jingjing，ZHOU Qiong，YAO Qin

Department of Clinical Pharmacy, the First Affiliated Hospital of Kunming Medical University, Kunming 650032, Yunnan, China

Received:2019-04-15 Revised:2019-06-27 Online:2019-09-26 Published:2019-09-26

摘要/Abstract

摘要：

选择性5-羟色胺再摄取抑制剂在临床应用中已成为一线抗抑郁药，其中艾司西酞普兰在临床被广泛用于治疗抑郁症，并取得了良好的治疗效果。但对于妊娠期抑郁症的患者，其妊娠期间使用艾司西酞普兰的资料有限。本文对艾司西酞普兰在妊娠期抑郁症患者中应用的安全性进行探讨。

关键词: 艾司西酞普兰, 抑郁, 妊娠, 安全性

Abstract:

5-hydroxytryptamine reuptake inhibitor (SSRIs) has become a first-line anti-depressant in clinic,among which escitalopram is widely used in the treatment of major depression,and has achieved good therapeutic effect.However,for patients with gestational depression,the safety of using escitalopram during pregnancy is still uncertain.The safety and effectiveness of escitalopram in patients with gestational depression was reviewed in this paper.

Key words: escitalopram, depression, gestational, pregnancy

中图分类号:

R749

王思捷，张峻，李骞，黄桦，王晶晶，周琼，姚勤. 艾司西酞普兰用于妊娠期抑郁的安全性研究探讨[J]. 中国临床药理学与治疗学, 2019, 24(9): 1070-1074.

WANG Sijie，ZHANG Jun，LI Qian，HUANG Hua，WANG Jingjing，ZHOU Qiong，YAO Qin. Research progress on the safety and effectiveness of escitalopram in the treatment of pregnant women with depression[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(9): 1070-1074.

参考文献

［1］汪天宇, 李英辉, 李磊, 等. 艾司西酞普兰治疗中国抑郁症患者有效性和安全性的Meta分析［J］. 中国临床药理学与治疗学, 2015, 20(9): 1020-1025.
［2］Si T, Wang G, Yang F, et al. Efficacy and safety of escitalopram in treatment of severe depression in Chinese population［J］. Metab Brain Dis, 2017, 32(3): 891-901.
［3］O'leary N, Jairaj C, Molloy EJ, et al.Antenatal depression and the impact on infant cognitive, language and motor development at six and twelve months postpartum［J］. Early Hum Dev, 2019, 134: 41-46.
［4］蒋海霞, 左洁, 卫小玉, 等. 产妇焦虑、抑郁情绪与分娩方式及不良分娩结局的关系［J］. 检验医学与临床, 2018, 15(5): 623-625,628.
［5］杨洋. 产前抑郁影响因素及其妊娠结局［J］. 中国计划生育学杂志, 2019, 27(4): 504-507.
［6］Zuckerman B, Amaro H, Bauchner H, et al. Depressive symptoms during pregnancy: relationship to poor health behaviors［J］. Am J Obstet Gynecol, 1989, 160(5 Pt 1): 1107-1111.
［7］Anderssion L,Sundstrom-popomaa I,Wulff M,et al.Implications of antenatal depression and anxiety for obstetric outcome［J］.Obstet Gynecol,2004,104(3):467-476.
［8］李大魁.治疗指南:精神病分册［M］. 2版. 北京:化学工业出版社, 2018:266-279.
［9］刘毅, 卓琳, 朱蓓, 等. 妊娠期抑郁症与新生儿低出生体重关系的Meta分析［J］. 中国当代儿科杂志, 2017, 19(9): 994-998.
［10］Betts KS, Williams GM, Najman JM, et al.Maternal depressive, anxious, and stress symptoms during pregnancy predict internalizing problems in adolescence［J］. Depress Anxiety, 2014, 31(1): 9-18.
［11］Van Batenburg-eddes T, Brion MJ, Henrichs J, et al. Parental depressive and anxiety symptoms during pregnancy and attention problems in children: a cross-cohort consistency study［J］.J Child Psychol Psychiatry, 2013, 54(5): 591-600.
［12］Otake Y, Nakajima S, Uno A, et al.Association between maternal antenatal depression and infant development: a hospital-based prospective cohort study［J］. Environ Health Prev Med, 2014, 19(1): 30-45.
［13］National Institute for Health and Care Excellence. An tenatal and postnatal mental health:clinical management and service guidance(CG192)［EB/OL］.(2014-12-17)［2018-03-13］.https://www.nice.org.uk/guidance/cg192/chapter/1-Recommendations.
［14］Fatima M, Srivastav S, Mondal AC. Prenatal stress and depression associated neuronal development in neonates［J］. Int J Dev Neurosci, 2017, 60: 1-7.
［15］Tsuchimine S, Ochi S, Tajiri M, et al. Effects of cytochrome P450 (CYP) 2C19 genotypes on steady-state plasma concentrations of escitalopram and its desmethyl metabolite in japanese patients with depression［J］. Ther Drug Monit, 2018, 40(3): 356-361.
［16］Bourke CH, Stowe ZN, Neigh GN, et al.Prenatal exposure to escitalopram and/or stress in rats produces limited effects on endocrine, behavioral, or gene expression measures in adult male rats［J］. Neurotoxicol Teratol, 2013, 39: 100-109.
［17］Ehrlich DE, Neigh GN, Bourke CH, et al.Prenatal stress, regardless of concurrent escitalopram treatment, alters behavior and amygdala gene expression of adolescent female rats［J］. Neuropharmacology, 2015, 97: 251-258.
［18］Rampono J, Simmer K, Ilett KF, et al. Placental transfer of SSRI and SNRI antidepressants and effects on the neonate［J］. Pharmacopsychiatry, 2009, 42(3): 95-100.
［19］Loughhead AM,Fisher AD,Newport DJ,et al.Antidepressants in amniotic fluid:another route of fetal exposure［J］.Am J Psychiatry,2006,163(1):145-147.
［20］Klieger-Grossmann C, Weitzner B, Panchaud A, et al.Pregnancy outcomes following use of escitalopram［J］. J Clin Pharmacol，2012,52(5): 766-770.
［21］Viktorin A, Uher R, Reichenberg A, et al. Autism risk following antidepressant medication during pregnancy［J］. Psychol Med, 2017, 47(16): 2787-2796.
［22］Reefhuis J, Devine O, Friedman JM, et al. Specific SSRIs and birth defects: Bayesian analysis to interpret new data in the context of previous reports［J］. BMJ, 2015, 351: h3190.
［23］Bellantuono C, Bozzi F, Orsolini L.Safety of escitalopram in pregnancy: a case series［J］. Neuropsychiatr Dis Treat, 2013, 9: 1333-1337.
［24］Orsolini L, Bozzi F, Bellantuono C.Psychopharmacological treatment in pregnancy and in breastfeeding: focus on escitalopram［J］. Eur Neuropsychopharmacol, 2013, (Suppl 2): S399-S400.
［25］Degiacomo J, Luedtke S. Neonatal toxicity from escitalopram use in utero: a case report［J］. J Pediatr Pharmacol Ther, 2016, 21(6): 522-526.
［26］Gentile S. Escitalopram late in pregnancy and while breast-feeding［J］. Ann Pharmacother, 2006, 40(9): 1696-1697.
［27］徐虹, 孙锟, 李智平, 等. 临床药物治疗学［M］. 北京:人民卫生出版社, 2016
［28］Cohen LS, Altshuler LL, Harlow BL, et al. Relapse of major depression during pregnancy in women who maintain or discontinue antidepressant treatment［J］. Jama, 2006, 295(5): 499-507.
［29］高杉, 黄桦, 王晶晶, 等. 5-羟色胺再摄取抑制剂在妊娠期抑郁患者中使用的安全性研究［J］. 中国药房, 2018, 29(17): 2439-2443.
［30］喻东山. 抗抑郁药对妊娠和哺乳的影响［J］. 临床精神医学杂志, 2012, 22(1): 60-62.
［31］白梦如, 孙冬黎, 蒋惠娣, 等. 胎盘中转运体的功能性表达与调控［J］. 药学学报, 2016, 51(6): 879-885.
［32］Wang JS, Newport DJ, Stowe ZN, et al. The emerging importance of transporter proteins in the psychopharmacological treatment of the pregnant patient［J］. Drug Metab Rev, 2007, 39(4): 723-746.
［33］Kliman HJ, Quaratella SB, Setaro AC, et al. Pathway of maternal serotonin to the human embryo and fetus［J］. Endocrinology, 2018, 159(4): 1609-1629.
［34］Joshi AA, Vaidya SS, St-pierre MV, et al. Placental ABC transporters: biological impact and pharmaceutical significance［J］. Pharm Res, 2016, 33(12): 2847-2878.
［35］Bundgaard C, Eneberg E, Sanchez C.P-glycoprotein differentially affects escitalopram, levomilnacipran, vilazodone and vortioxetine transport at the mouse blood-brain barrier in vivo［J］. Neuropharmacology, 2016, 103: 104-111.
［36］Zhu HJ, Appel DI, Grundemann D, et al. Evaluation of organic cation transporter 3 (SLC22A3) inhibition as a potential mechanism of antidepressant action［J］. Pharmacol Res, 2012, 65(4): 491-496.
［37］Huang H, Wang J, Li Q, et al. Transplacental transfer of oseltamivir phosphate and its metabolite oseltamivir carboxylate using the ex vivo human placenta perfusion model in Chinese Hans population［J］. J Matern Fetal Neonatal Med, 2017, 30(11): 1288-1292.

[1]	肖悦, 李唐菲, 薛乾富. 聚乙二醇干扰素-α治疗原发性血小板增多症的疗效和安全性分析[J]. 中国临床药理学与治疗学, 2023, 28(9): 1049-1055.
[2]	张涛涛, 苏文秀, 田利民. 亚临床甲状腺功能减退症和抑郁的相关性研究进展[J]. 中国临床药理学与治疗学, 2023, 28(8): 954-960.
[3]	刘敏, 孔祥, 章叶, 顾逸飞, 项雪梅, 黄凯. 经口吸入制剂在中国健康受试者生物等效性试验中的安全性分析[J]. 中国临床药理学与治疗学, 2023, 28(10): 1131-1138.
[4]	梁美芳, 陈庆状, 杨沛群, 王勇. 基于真实世界的阿托伐他汀仿制药和原研药防治缺血性脑卒中/短暂性脑缺血发作的有效性和安全性比较[J]. 中国临床药理学与治疗学, 2022, 27(7): 785-792.
[5]	于泽芳, 范理菊, 尹晓玉, 高丽丽, 董占军. 新型速效抗抑郁药的研究进展[J]. 中国临床药理学与治疗学, 2022, 27(5): 595-600.
[6]	何滕, 许向阳, 徐祥清, 刘存明, 杨春. 氯胺酮治疗抑郁症的过去、现在及未来[J]. 中国临床药理学与治疗学, 2022, 27(10): 1125-1132.
[7]	刘馨, 冷玉芳, 张学红, 张莉莉, 张梦婕, 瞿珊珊, 谢建琴, 王一青. 纳布啡在超声引导下经阴道穿刺取卵术中的应用及对胚胎质量和妊娠结局的影响[J]. 中国临床药理学与治疗学, 2021, 26(9): 1042-1047.
[8]	鲍静, 陈晓文, 夏亮, 赵雨辰, 夏瑞祥, 夏海龙. 伊沙佐米治疗多发性骨髓瘤的临床疗效和安全性分析[J]. 中国临床药理学与治疗学, 2021, 26(7): 782-786.
[9]	王叶情, 王宇红, 刘检, 赵洪庆, 邹蔓姝. 胆囊收缩素与抑郁症的相关性研究进展[J]. 中国临床药理学与治疗学, 2021, 26(6): 672-679.
[10]	陈颖, 袁勇贵. 中药单体、药对、复方、中成药治疗抑郁症研究进展[J]. 中国临床药理学与治疗学, 2021, 26(5): 586-593.
[11]	金晶, 程虹. 线粒体能量代谢参与抑郁症发病的研究进展[J]. 中国临床药理学与治疗学, 2021, 26(10): 1193-1199.
[12]	江伟杰, 贺海波, 唐红波, 贺君宇. 胎盘组织核因子-κB与妊娠并发症关系研究进展[J]. 中国临床药理学与治疗学, 2021, 26(1): 82-87.
[13]	杨世涛, 祝一虹, 唐文新. 阿立哌唑联合度洛西汀对难治性抑郁的疗效及对血管内皮生长因子的作用研究[J]. 中国临床药理学与治疗学, 2020, 25(8): 937-942.
[14]	黄好, 肖芳, 贾虹, 王晓霜, 段亚亭. 妊娠期糖尿病中患者miR-138-5p通过调控缺氧诱导因子1α保护β细胞功能[J]. 中国临床药理学与治疗学, 2020, 25(5): 489-497.
[15]	葛薇，盛文燕，许琦彬，李秋实，苏铃雅，吴双庆. 选择性5-羟色胺再摄取抑制剂类抗抑郁药舍曲林对产后抑郁患者眼表功能影响[J]. 中国临床药理学与治疗学, 2020, 25(4): 440-446.

艾司西酞普兰用于妊娠期抑郁的安全性研究探讨

Research progress on the safety and effectiveness of escitalopram in the treatment of pregnant women with depression

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价